Benjamin Edwards Inc. Raises Holdings in Danaher Co. (NYSE:DHR)

Benjamin Edwards Inc. raised its holdings in Danaher Co. (NYSE:DHR) by 1.8% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,153 shares of the conglomerate’s stock after purchasing an additional 38 shares during the quarter. Benjamin Edwards Inc.’s holdings in Danaher were worth $538,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of DHR. Cape Investment Advisory Inc. purchased a new stake in Danaher in the 4th quarter valued at about $25,000. Tsfg LLC lifted its holdings in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. purchased a new position in shares of Danaher during the 2nd quarter worth approximately $25,000. nVerses Capital LLC acquired a new stake in Danaher in the 2nd quarter valued at approximately $25,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in Danaher in the first quarter valued at approximately $30,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Activity at Danaher

In related news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock valued at $11,042,433 in the last ninety days. Insiders own 11.10% of the company’s stock.

Danaher Stock Down 1.4 %

Danaher stock opened at $272.63 on Friday. The stock has a market cap of $201.93 billion, a PE ratio of 46.21, a P/E/G ratio of 4.48 and a beta of 0.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The stock’s fifty day moving average is $267.62 and its two-hundred day moving average is $257.14. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business’s quarterly revenue was down 2.9% on a year-over-year basis. During the same quarter last year, the company earned $2.05 EPS. On average, sell-side analysts expect that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s payout ratio is 18.31%.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Royal Bank of Canada restated an “outperform” rating and set a $300.00 price target on shares of Danaher in a research report on Friday, September 6th. Robert W. Baird raised their target price on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. TD Cowen boosted their price target on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Jefferies Financial Group started coverage on shares of Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective for the company. Finally, The Goldman Sachs Group upped their target price on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, Danaher has an average rating of “Moderate Buy” and a consensus target price of $278.94.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.